{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:37:29Z","timestamp":1789580249573,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373044"],"award-info":[{"award-number":["82373044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022LSW001"],"award-info":[{"award-number":["ZR2022LSW001"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.cpt.2023.11.005","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T13:01:57Z","timestamp":1701435717000},"page":"164-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Common endocrine system adverse events associated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"2","author":[{"given":"Ying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1935-9214","authenticated-orcid":false,"given":"Junfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-8900","authenticated-orcid":false,"given":"Yintao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2023.11.005_bib1","first-page":"86","article-title":"A\u00a0review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cpt.2023.11.005_bib2","doi-asserted-by":"crossref","first-page":"100011","DOI":"10.1016\/j.esmoop.2020.100011","article-title":"How we treat endocrine complications of immune checkpoint","volume":"6","author":"Paschou","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.cpt.2023.11.005_bib3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.cpt.2023.11.005_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.cpt.2023.11.005_bib5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cpt.2023.11.005_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cpt.2022.12.002","article-title":"Role of T cells in cancer immunotherapy: opportunities and challenges","volume":"1","author":"Ahmed","year":"2023","journal-title":"Cancer Pathog Ther"},{"key":"10.1016\/j.cpt.2023.11.005_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.cpt.2023.11.005_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.cpt.2023.11.005_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101370","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.cpt.2023.11.005_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.tem.2021.10.009","article-title":"The changing clinical spectrum of endocrine adverse events in cancer immunotherapy","volume":"33","author":"Chiloiro","year":"2022","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.cpt.2023.11.005_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.cpt.2023.11.005_bib12","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cpt.2023.11.005_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tips.2019.11.003","article-title":"Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy","volume":"41","author":"Liu","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.cpt.2023.11.005_bib14","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.cpt.2023.11.005_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13578-018-0229-z","article-title":"Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?","volume":"8","author":"Tang","year":"2018","journal-title":"Cell Biosci"},{"key":"10.1016\/j.cpt.2023.11.005_bib16","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.cpt.2023.11.005_bib17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5603\/EP.a2018.0073","article-title":"Endocrine complications of cancer immunotherapy","volume":"69","author":"Kr\u00f3l","year":"2018","journal-title":"Endokrynol Pol"},{"key":"10.1016\/j.cpt.2023.11.005_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.cpt.2023.11.005_bib19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.cpt.2023.11.005_bib20","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpt.2023.11.005_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.cpt.2023.11.005_bib22","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Ott","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpt.2023.11.005_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2017.08.019","article-title":"Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach","volume":"47","author":"Iglesias","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cpt.2023.11.005_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf5107","article-title":"LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade","volume":"13","author":"Shen","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cpt.2023.11.005_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107933","article-title":"TIM-3: an update on immunotherapy","volume":"99","author":"Zhao","year":"2021","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.cpt.2023.11.005_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2020.07.001","article-title":"News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors","volume":"79","author":"Melaiu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.cpt.2023.11.005_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.cpt.2023.11.005_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cpt.2023.11.005_bib29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpt.2023.11.005_bib30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2217\/imt-2016-0002","article-title":"Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges","volume":"8","author":"Kyi","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.cpt.2023.11.005_bib31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cpt.2023.11.005_bib32","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cpt.2023.11.005_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpt.2023.11.005_bib34","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jhep.2018.08.014","article-title":"Incidence of grade 3\u20134 liver injury under immune checkpoints inhibitors: a retrospective study","volume":"69","author":"Parlati","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cpt.2023.11.005_bib35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.cpt.2023.11.005_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101635","article-title":"Endocrine immune-related adverse events: adrenal, parathyroid, diabetes insipidus, and lipoatrophy","volume":"36","author":"Atkinson","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.cpt.2023.11.005_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cpt.2023.11.005_bib38","doi-asserted-by":"crossref","first-page":"m736","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","volume":"369","author":"Chan","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cpt.2023.11.005_bib39","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/00325481.2019.1709344","article-title":"Immune checkpoint inhibitors and endocrine side effects, a narrative review","volume":"132","author":"Agrawal","year":"2020","journal-title":"Postgrad Med"},{"key":"10.1016\/j.cpt.2023.11.005_bib40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40618-019-01112-8","article-title":"Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study","volume":"43","author":"Presotto","year":"2020","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.cpt.2023.11.005_bib41","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.cpt.2023.11.005_bib42","doi-asserted-by":"crossref","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.cpt.2023.11.005_bib43","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.cpt.2023.11.005_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.cpt.2023.11.005_bib45","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.cpt.2023.11.005_bib46","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1089\/thy.2017.0062","article-title":"Anti-PD-1 antibody therapy induces Hashimoto's disease with an increase in peripheral blood follicular helper T cells","volume":"27","author":"Torimoto","year":"2017","journal-title":"Thyroid"},{"key":"10.1016\/j.cpt.2023.11.005_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A\u00a0systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.cpt.2023.11.005_bib48","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/cam4.1145","article-title":"Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists","volume":"6","author":"Illouz","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.cpt.2023.11.005_bib49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/fcp.12453","article-title":"Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National pharmacovigilance database","volume":"33","author":"Castinetti","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.cpt.2023.11.005_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.hoc.2018.12.008","article-title":"Immunotherapy toxicity","volume":"33","author":"Mantia","year":"2019","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.cpt.2023.11.005_bib51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cpt.2023.11.005_bib52","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13181-021-00833-8","article-title":"A\u00a0review of cancer immunotherapy toxicity: immune checkpoint inhibitors","volume":"17","author":"Chhabra","year":"2021","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.cpt.2023.11.005_bib53","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune Checkpointm inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.cpt.2023.11.005_bib54","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1530\/EC-19-0473","article-title":"Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction","volume":"9","author":"Olsson-Brown","year":"2020","journal-title":"Endocr Connect"},{"key":"10.1016\/j.cpt.2023.11.005_bib55","first-page":"1736","article-title":"Endocrine side effects of cancer immunotherapy","volume":"145","author":"Kroi\u00df","year":"2020","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.cpt.2023.11.005_bib56","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cpt.2023.11.005_bib57","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cpt.2023.11.005_bib58","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi","year":"2019","journal-title":"Expet Rev Endocrinol Metabol"},{"key":"10.1016\/j.cpt.2023.11.005_bib59","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.crad.2020.12.028","article-title":"The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients","volume":"76","author":"Lasocki","year":"2021","journal-title":"Clin Radiol"},{"key":"10.1016\/j.cpt.2023.11.005_bib60","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/ijms20102560","article-title":"Autoimmune endocrine dysfunctions associated with cancer immunotherapies","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpt.2023.11.005_bib61","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.cpt.2023.11.005_bib62","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.cpt.2023.11.005_bib63","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study","volume":"35","author":"Apolo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpt.2023.11.005_bib64","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpt.2023.11.005_bib65","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cpt.2023.11.005_bib66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.cpt.2023.11.005_bib67","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20182232","article-title":"PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance","volume":"218","author":"Tan","year":"2021","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cpt.2023.11.005_bib68","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.2337\/dc18-2518","article-title":"T-lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpt.2023.11.005_bib69","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor-associated diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpt.2023.11.005_bib70","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.cpt.2023.11.005_bib71","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2169\/internalmedicine.9518-17","article-title":"Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody","volume":"57","author":"Shiba","year":"2018","journal-title":"Intern Med"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713223000940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713223000940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:50:50Z","timestamp":1778935850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713223000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2949713223000940"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2023.11.005","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Common endocrine system adverse events associated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2023.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}